Additionally, GLP-1RAs protect against CVD by improving endothelial dysfunction, an early phase of atherosclerosis [28,29], triggered by high blood pressure, diabetes, and elevated cholesterol [30,31]
In addition, in patients with DT2, there is the possibility of using an oral presentation of semaglutide
Ozempic seized the spotlight first
(2018) reviewed BPC-157s effects on the brain-gut axis in Current Neuropharmacology (PMID: 28707506), documenting protective effects against NSAIDinduced gastric lesions, inflammatory bowel disease models, and neurological injury models
But actual results can vary based on an individual: Talk with your doctor to determine a realistic timeline after factoring in your attributes and risk factors